E-Z-EM Named One of New York Area's Top Public Companies by Crain's New York Business
31 May 2005
E-Z-EM, Inc., (NASDAQ:EZEM - News) today announced that the Company has been included in Crain's New York Business's list of the 300 largest publicly held companies in the New York area. The list ranks companies by their 2004 revenues. For E-Z-EM, this included its former subsidiary AngioDynamics, which was spun off to E-Z-EM shareholders in October of 2004.
Anthony A. Lombardo, President and CEO of E-Z-EM, commented, "The New York area has among the highest concentration of prominent businesses in the U.S. so we are very pleased to be included in this ranking."
The list of "New York Area's Largest Publicly Held Companies" is included in the May 23, 2005 issue of Crain's New York Business. The information was compiled by Standard & Poor's, a division of The McGraw-Hill Cos., from its database of publicly held companies. Companies must have their headquarters in New York City, in Westchester County, on Long Island, or in one of four counties in northern New Jersey: Bergen, Essex, Hudson or Union.
About E-Z-EM, Inc.
E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company recently introduced VoLumen® the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and PET/CT studies. The Company also offers Empower® -- the only family of CT injectors on the market with patented EDA(TM) technology that can help detect contrast extravasation -- and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.
The statements made in this document contain certain forward-looking statements. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company's control. Such risks and uncertainties include the ability of the Company to develop its products, the results of ongoing medical research for and market acceptance of VoLumen, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 26, 2005 and its Annual Report on Form 10-K for the fiscal year ended May 29, 2004. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.
--------------------------------------------------------------------------------
Contact:
E-Z-EM, Inc.
Tom Johnson (tjohnson@ezem.com)
800-544-4624 x3317
www.ezem.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
Lisa Lindberg (llindberg@lhai.com)
212-838-3777
Bruce Voss (bvoss@lhai.com)
310-691-7100
--------------------------------------------------------------------------------
Source: E-Z-EM, Inc.
Source: Business Wire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
